Advertisement

Search Results

Advertisement



Your search for ,itS matches 8694 pages

Showing 751 - 800


A Father’s Advice Plus a Desire to Help Spur a Career in Oncology and a Leadership Role in African Cancer Care

Miriam Mutebi, MD, MSc, FACS, was born and reared in the outskirts of Nairobi, Kenya. “The suburb I grew up in (Langata), has seen a lot of development over the past couple of decades. When I was a child, it was a smaller community, where you would go and play at somebody else’s house and have...

Immigrant Reared During the Lebanese Civil War by Parents Who Valued Education Becomes a Leader in Genitourinary Oncology

Genitourinary cancer expert Toni K. Choueiri, MD, FASCO, was born in 1975 in Beirut, Lebanon, the year a devastating civil war erupted, lasted for 15 years, and cost the lives of some 150,000 individuals and also led to the exodus of almost 1 million people from Lebanon. “People with the financial...

Born in a Small Village in India, a Breast Cancer Expert Assumes a Leadership Role in Oncology in Cleveland and Beyond

Jame Abraham, MD, FACP, was born and reared in Kerala, a tropical state in southwestern India. Situated on the Malabar Coast, Kerala was named as one of the ten paradises of the world by National Geographic Traveler. “Along with its natural beauty, Kerala is a true melting pot. Over centuries,...

Multicultural ASCO President-Elect Was Raised in Mexico by Parents Who Instilled a Sense of Duty to Make a Difference

ASCO President-Elect Eric J. Small, MD, FASCO, developed much of his multicultural world view during his childhood in Mexico City. “My parents were expatriates who moved to Mexico in the 1950s and settled there. I was born in Mexico City and grew up bilingually. I went to an English-Spanish...

breast cancer

Be Prepared: A Patient Perspective

I’m not prepared. It could be a few months, a few years, maybe longer. I don’t know how bad the verdict will be, but whatever it is, I’m not prepared. They always told us to be prepared. That was our motto. At age 7, I joined the Brownies, the beginning of 12 years of being molded by Girl Scout...

solid tumors
issues in oncology
symptom management

ASTRO Releases Updated Clinical Guidelines on Radiation Therapy for Patients With Bone Metastases

The American Society for Radiation Oncology (ASTRO) outlined recommendations on best practices for treating patients with symptomatic bone metastases and strategies to improve their quality of life, according to updated clinical guidelines published by Alcorn et al in Practical Radiation Oncology....

immunotherapy

Introducing ASPIRE and STORIES: A New International Initiative for Faculty Collaboration and Patient Advocacy in Immune-Related Adverse Events

The Immune-Related Adverse Events (irAE) Consortium has launched ASPIRE and STORIES with the aim of uniting clinicians, researchers, and patients to advance clinical care and advocacy. As the indications for immune checkpoint inhibitors in oncology have rapidly expanded over the past decade, the...

issues in oncology

The Future of Cancer Care

The profound progress in cancer care since President Richard Nixon signed the National Cancer Act of 1971 into law is evidenced by the soaring number of cancer survivors since the law went into effect. In the 1970s, there were 3 million cancer survivors1; today, there are more than 18 million, and...

pancreatic cancer

Is a Test for Early Detection of Pancreatic Cancer on the Horizon?

An investigational noninvasive exosome-based liquid biopsy shows potential for early detection of pancreatic cancer, an important unmet need, according to research presented at the American Association for Cancer Research (AACR) Annual Meeting 2024.1 When combined with the biomarker CA 19-9, the...

A Look Back on an Impactful and Inspiring Presidential Year

Serving as ASCO’s 60th President over the past year has been an honor and a privilege, said Lynn M. Schuchter, MD, FASCO, who will end her Presidential term during ASCO’s Annual Meeting, being held from May 31 to June 4, 2024, in Chicago, and welcome incoming President Robin Zon, MD, FACP, FASCO,...

supportive care

Dance/Movement Therapy for Pediatric Oncology Patients and Their Caregivers

Guest Editor’s Note: Children with cancer and their caregivers face physical and psychosocial challenges during and after treatment. Dance/movement therapy has been used to improve well-being, promote healthy coping, and mitigate the impact of illness, but limited knowledge exists regarding its...

Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, Joins Perthera as Chief Medical Officer

Perthera, an industry leader in precision oncology decision support, recently announced that Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, joined Perthera as Chief Medical Officer. Dr. Raghavan is founding President of the Levine Cancer Institute and former Chair and Director of the Cleveland...

issues in oncology

Understanding the Legal and Ethical Challenges AI Poses in Oncology

The field of oncology is experiencing a revolution driven by artificial intelligence (AI) technology. Artificial intelligence tools are already being used in medical imaging analysis, treatment planning, and even patient counseling. These advancements hold immense promise for earlier cancer...

issues in oncology

HPV Vaccine Shows Prevention Efficacy for Several Types of HPV-Related Cancers in Both Males and Females

According to the Centers for Disease Control and Prevention, since the human papillomavirus (HPV) vaccine was introduced in the United States in 2006, HPV infections that cause most HPV-related cancers and genital warts have decreased by 88% among teenage girls and 81% among young adult women. Now, ...

gynecologic cancers

HPV Screening Intervals for Cervical Cancer May Be Safely Extended Beyond Current 5-Year Recommendation, Study Finds

A longitudinal cohort study published by Gottschlich et al in Cancer Epidemiology, Biomarkers & Prevention investigated the optimal interval between screening tests and the long-term risk of cervical precancer or worse (CIN2+). Researchers found that the risk of cervical precancer 8 years after ...

prostate cancer
issues in oncology

Sexual Well-Being in the Female Partners of Patients With Prostate Cancer

The female partners of patients with prostate cancer may experience quality-of-life issues that impact their sexual well-being, according to a recent study published by Loeb et al in European Urology Oncology. Background Prostate cancer—one of the most common cancer types in U.S. men—and its...

hematologic malignancies
issues in oncology

Metformin May Help Reduce the Risk of Developing Myeloproliferative Neoplasms

Treatment with metformin may be associated with a lower risk of developing myeloproliferative neoplasms over time, according to a recent study published by Kristensen et al in Blood Advances. Background Myeloproliferative neoplasms are a group of diseases that develop over long periods of time and...

gastroesophageal cancer
gastrointestinal cancer

Advanced Gastric or Gastroesophageal Junction Cancer: Addition of Relatlimab to Immunochemotherapy

In the phase II RELATIVITY-060 study, results of which were reported in the Journal of Clinical Oncology, Susanna Hegewisch-Becker, MD, PhD, and colleagues found that the addition of the LAG-3–blocking antibody relatlimab to first-line nivolumab plus chemotherapy did not improve the objective...

multiple myeloma
breast cancer
bladder cancer
gynecologic cancers
skin cancer
pancreatic cancer

NCCN Clinical Practice Guidelines in Oncology: 2024 Updates

The National Comprehensive Cancer Network® published its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Currently, guidelines are available for more than 60 tumor types, subtypes, and related topics. The NCCN’s 29th Annual Conference...

multiple myeloma

Multiple Myeloma: Is MRD Status at 1 Year After Treatment Predictive of Survival?

Results from the Prognostic Immunophenotyping in Myeloma Response (PRIMeR) study, reported in the Journal of Clinical Oncology by Marcelo C. Pasquini, MD, MS, and colleagues, found that undetectable measurable residual disease (MRD) status at 1 year after autologous hematopoietic cell...

palliative care

Providing Culturally Sensitive Palliative Care to Children With Cancer

In the fall of 2023, Justin Baker, MD, took on the role of Chief of the Division of Quality of Life and Pediatric Palliative Care and Director of the Quality of Life for All Program, Stanford Medicine Children’s Health, Stanford, California. He formerly worked at St. Jude Children’s Research...

Daniel M. Geynisman, MD, Named New JNCCN Editor-in-Chief

Daniel M. Geynisman, MD, has been announced as the new Editor-in-Chief for JNCCN—Journal of the National Comprehensive Cancer Network. Dr. Geynisman is Associate Professor in the Department of Hematology/Medical Oncology and Chief of the Division of Genitourinary Medical Oncology at Fox Chase...

gynecologic cancers

FDA Approves HPV Self-Collection Solution

On May 15, Roche announced the U.S. Food and Drug Administration (FDA) approval of its human papillomavirus (HPV) self-collection solution—one of the first of such tests available in the United States. Screening for HPV can help identify women who are at risk of developing cervical cancer so that...

solid tumors
hematologic malignancies

Children’s Cancer Cause Opens Applications for the 2024 Survivorship Champion’s Prize

The Children’s Cancer Cause announced that the organization is accepting applications for its 2024 Survivorship Champion’s Prize. Overview of the Prize The Survivorship Champion’s Prize, totaling $10,000, is presented by Children’s Cancer Cause annually to a group, program, or institution...

colorectal cancer

Appendectomy May Lower Risk of Colorectal Cancer Subtype

Appendectomy may be associated with a reduced risk of a colorectal cancer subtype positive for the tumor-promoting Fusobacterium nucleatum bacteria, according to a recent study published by Kawamura et al in the Annals of Surgery. Background Despite being historically dismissed as an unnecessary...

leukemia
geriatric oncology
issues in oncology

Venetoclax Plus Hypomethylating Agents: Analyzing Standard-of-Care Outcomes in Older Patients With AML

Standard-of-care treatment comprising venetoclax plus hypomethylating agents was found to be safe and effective in some patients aged 80 years and older with acute myeloid leukemia (AML), according to a recent study published by Madarang et al in Blood Neoplasia. Background Older adult patients...

kidney cancer

Belzutifan in Previously Treated Advanced Renal Cell Carcinoma

On December 14, 2023, the hypoxia-inducible factor inhibitor belzutifan (Welireg) was approved for patients with unresectable locally advanced or metastatic clear cell renal cell carcinoma with disease progression on previous treatment with a PD-1 or PD-L1 inhibitor and a vascular endothelial...

issues in oncology

AI in Cancer Care: Embrace the Change

According to Google Chief Executive Officer Sunder Pichai, artificial intelligence (AI) is “the most profound technology humanity is working on—more profound than fire or electricity or anything that we’ve done in the past.” The impact of AI on health care and especially cancer care will not be...

head and neck cancer

Two Studies Support Deintensification of Treatment for HPV-Associated Oropharyngeal Cancer

Two studies presented at the 2024 Multidisciplinary Head and Neck Cancers Symposium added support for the deintensification of radiotherapy in early-stage oropharyngeal squamous cell cancers associated with the human papillomavirus (HPV), a subtype typically more responsive to therapy compared to...

gynecologic cancers

For Detection of Measurable Residual Disease in Ovarian Cancer, Are Two Methods Better Than One?

In patients with ovarian cancer, second-look surgery may find a role again. The evaluation of measurable residual disease (MRD) using second-look laparoscopy identified more women who had detectable MRD after front-line treatment than did circulating tumor DNA (ctDNA), according to a study...

lung cancer

Durvalumab After Chemoradiotherapy in Unresectable NSCLC: Real-World Use and Outcomes

In a U.S. retrospective cohort study (SPOTLIGHT) reported in JAMA Network Open, Mooradian et al found that a substantial proportion of patients with unresectable stage III non–small cell lung cancer (NSCLC) did not receive consolidation durvalumab after chemoradiotherapy—but those who did had...

lung cancer

Liposomal Irinotecan vs Topotecan in Relapsed Small Cell Lung Cancer

As reported in the Journal of Clinical Oncology by David R. Spigel, MD, and colleagues, the phase III RESILIENT Part 2 trial has shown no overall survival benefit with second-line liposomal irinotecan vs topotecan in patients with small cell lung cancer whose disease progressed on or after...

breast cancer
gastroesophageal cancer
gastrointestinal cancer

FDA Approves Trastuzumab Biosimilar Trastuzumab-strf

The U.S. Food and Drug Administration (FDA) has approved trastuzumab-strf (Hercessi), a biosimilar to trastuzumab (Herceptin), for the treatment of HER2-overexpressing breast cancer and gastric or gastroesophageal junction adenocarcinoma. Trastuzumab-strf is indicated for adjuvant treatment of...

head and neck cancer

Can HPV Circulating Tumor DNA Guide Adjuvant Treatment of Oropharyngeal Cancer?

Although so-called liquid biopsies are now helping to determine the need for adjuvant therapy for a number of malignancies, oropharyngeal carcinoma is not yet one of them, according to a prospective pilot study from Memorial Sloan Kettering Cancer Center. The investigators evaluated the use of...

gynecologic cancers

Survival Benefit Emerges With Use of Dostarlimab-gxly Plus Chemotherapy in Advanced or Recurrent Endometrial Cancer

The addition of a checkpoint inhibitor to standard chemotherapy as first-line treatment of advanced or recurrent endometrial cancer not only reduced the risk of disease progression but improved overall survival, particularly for the mismatch repair–deficient/microsatellite instability–high...

colorectal cancer

Adagrasib Plus Cetuximab: Potential Option for KRAS G12C–Mutated Colorectal Cancer

Although KRAS was once considered an untargetable mutation, KRAS inhibitors are now approved for the treatment of KRAS-mutated non–small cell lung cancer (NSCLC) and are emerging as a potential option for the treatment of KRAS G12C–mutated colorectal cancer in combination with other therapies....

colorectal cancer
supportive care

Potential Protective Effects of Aspirin Against Colorectal Cancer

Researchers may have uncovered how the long-term daily use of aspirin may help prevent the development and progression of colorectal cancer, according to a recent study published by De Simoni et al in Cancer. Study Methods and Results In the recent study, the researchers collected the tissue...

pain management

Comparative Effectiveness of Acupuncture vs Massage for Relieving Pain in Patients With Advanced Cancer

  Pain, a debilitating consequence of cancer and its treatments, is highly prevalent among patients with advanced cancer.1 Often persistent and undertreated, it is associated with poor functional and emotional well-being and typically occurs along with insomnia and fatigue.2 The use of opioids,...

breast cancer
issues in oncology

The Lancet Commission on Breast Cancer: Reducing Overlooked Inequities in Breast Cancer

Investigators have uncovered persistent inequities in breast cancer that may systematically leave many patients behind in spite of recent improvements in research, treatment, and survival, according to a recent report from The Lancet Breast Cancer Commission. These findings were published by Coles...

breast cancer
global cancer care

A Pioneering Female Oncologist in Morocco Helps Advance the Global Shift Toward Gender Equity in Academia

Success stories in research, advocacy, and education from low- and middle-income countries deserve international recognition to motivate the next generation of researchers and practitioners and enrich global oncology. I recently had the privilege to speak with Ouissam Al Jarroudi, MD, about her...

gynecologic cancers

Progression-Free Survival Benefit Confirmed With Triplet Combination in BRCA Wild-Type, HRD-Positive Ovarian Cancer

The combination of immunotherapy, targeted therapy, and chemotherapy could be the new standard first-line treatment of patients with high-grade, advanced ovarian cancer with BRCA wild-type, homologous recombination deficiency (HRD)-positive tumors, according to data presented during the Society of...

geriatric oncology

Exploring Geriatric Assessment Effectiveness: Insights From the 2023 International Society of Geriatric Oncology Conference

Geriatric assessment has emerged as a pivotal tool in optimizing cancer care for older patients, aiming to mitigate treatment toxicity, enhance treatment adherence, and improve quality of life. The recommended areas for evaluation in a geriatric assessment focus on identifying health issues that...

lung cancer
issues in oncology

Radon Gas Exposure May Be Linked to Increased Incidence of Lung Cancer in Nonsmokers

Long-term exposure to radon gas may be associated with a rise in nonsmoking lung cancer cases, according to a recent consumer survey conducted on behalf of The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James)....

supportive care
survivorship

Effect of Virtually Delivered CBT for Insomnia on Cancer-Related Cognitive Impairment

In a Canadian study reported in the Journal of Clinical Oncology, Sheila N. Garland, PhD, and colleagues found that virtually delivered cognitive behavioral therapy for insomnia (CBT-I) improved perceived cancer-related cognitive impairment (CRCI) vs waiting list controls in cancer survivors. Study ...

prostate cancer
genomics/genetics

Proteogenomic Signatures May Help Identify Risk of Prostate Cancer Progression in Certain Populations

Certain proteogenomic signatures in the prostate cancers of men of African and European ancestries were associated with higher risk of metastasis and/or recurrence of the disease, according to a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 (Abstract...

issues in oncology

AACR Inaugurates New Leadership

The members of the American Association for Cancer Research (AACR) elected a new 2024 to 2025 President and President-Elect at the AACR’s Annual Business Meeting of Members during the AACR Annual Meeting 2024 in San Diego. New President The AACR welcomed Patricia M. LoRusso, DO, PhD (hc), FAACR, as ...

cns cancers

ATM Kinase Inhibitor Plus Radiotherapy for Patients With Glioblastoma

AZD1390, an ataxia telangiectasia mutant (ATM) kinase inhibitor, demonstrated a manageable safety profile in patients with both recurrent and newly diagnosed glioblastoma when given in combination with standard-of-care radiotherapy and showed preliminary efficacy in patients with recurrent...

colorectal cancer

Adagrasib Plus Cetuximab in KRAS G12C–Mutated Colorectal Cancer

The combination of the KRAS G12C inhibitor adagrasib and the anti-EGFR antibody cetuximab showed clinical activity and promising survival outcomes in a cohort of patients with metastatic, heavily pretreated, KRAS G12C–mutated colorectal cancer, according to results from the phase I/II KRYSTAL-1...

pancreatic cancer

Immune Response to Investigational RNA Vaccine for Pancreatic Cancer Continues to Correlate With Clinical Benefit

An adjuvant treatment regimen that included autogene cevumeran, an investigational individualized neoantigen-specific mRNA vaccine, induced durable and functional T-cell responses that were associated with a reduced risk of disease recurrence in certain patients with resectable pancreatic cancer,...

gynecologic cancers
immunotherapy

Mirvetuximab Soravtansine Plus Pembrolizumab in Patients With Endometrial Cancer Subtype

The combination of the antibody-drug conjugate mirvetuximab soravtansine-gynx and the immune checkpoint inhibitor pembrolizumab showed notable activity in patients with recurrent or persistent microsatellite-stable endometrial cancer, according to new findings presented by Porter et al at the...

Advertisement

Advertisement




Advertisement